The prognostic value of integration of pretreatment serum amyloid A (SAA)–EBV DNA (S-D) grade in patients with nasopharyngeal carcinoma

Clinical and Translational Medicine

Table 5 Relationship between the SAA and EBV DNA pretreatment and the clinical characteristics in 304 patients with NPC

Variables	SAA (mg/L)			EBV DNA (copies/mL)			S-D Grade
Variables	≤ 4.46 (n = 154)	> 4.46 (n = 150)	P	≤ 2340 (n = 161)	> 2340 (n = 143)	P	1 (n = 92)	2 (n = 131)	3 (n = 81)	P
Gender
Male	114	118	0.349	123	109	1.000	70	97	65	0.586
Female	40	32	0.349	38	34	1.000	22	34	16	0.586
Age (years)
≤ 46	76	81	0.424	80	77	0.492	46	64	47	0.401
> 46	78	69	0.424	81	66	0.492	46	67	34	0.401
Tumor stage
T1–2	32	20	0.095	34	18	0.066	22	22	8	0.050
T3–4	122	130	0.095	127	125	0.066	70	109	73	0.050
Node stage
N0–1	95	73	0.028	118	50	<0.001	66	81	21	<0.001
N2–3	59	77	0.028	43	93	<0.001	26	50	60	<0.001
TNM stage
I	5	3	0.016	7	1	<0.001	5	2	1	<0.001
II	18	7		18	7		13	10	2
III	81	68		94	55		52	71	26
IV	50	72		42	80		22	48	52
Treatment
Radiotherapy	28	15	0.048	32	11	0.003	21	18	4	0.003
Chemoradiotherapy	126	135	0.048	129	132	0.003	71	113	77	0.003